Beam Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Beam Therapeutics

08/08/2023 13:07

* Beam Therapeutics Inc  BEAM.OQ  reported a quarterly
adjusted
loss of $1.08​​ per share for the quarter ended in June. The
mean expectation of thirteen analysts for the quarter was for a
loss of $1.42 per share.
    * Revenue rose 20.8% to $20.12 million from a year ago;
analysts
expected $18.05 million. 
    * Beam Therapeutics Inc's reported EPS for the quarter was a
loss
of $1.08​.
    * The mean earnings estimate of analysts had fallen by
about 3.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Beam Therapeutics Inc shares had fallen by 20.0% this
quarter and lost 34.7% so far this year.
    * The company reported a quarterly loss of $82.78 million.
    * Wall Street's median 12-month price target for Beam
Therapeutics
Inc is $60.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 12:07 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -1.42          -1.08          Beat
 Mar. 31 2023      -1.34          -1.33          Beat
 Dec. 31 2022      -1.33          -0.54          Beat
 Sep. 30 2022      -1.31          -1.56          Missed